TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05381415

Intervention type: OTHER
Intervention: Inhalation of bronchodilation therapy at FRC
Description: the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from FRC (functional residual capacity, in a random order, with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation.

Intervention type: OTHER
Intervention: Inhalation of bronchodilation therapy at RV
Description: the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR , with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation.
Study: NCT05573880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galileo Med35
Description: whole-body vibration training on the platform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galileo Med35
Description: whole-body vibration training on the platform
Study: NCT04757662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil is commercially available and will be purchased by the Siteman Cancer Center and distributed to participants free of charge.
Study: NCT06452498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule filled with cellulose.
Study: NCT05660759

Intervention type: PROCEDURE
Intervention: Portal vein embolization
Description: Portal vein emboliazation with either NBCA or micro particles.

Intervention type: PROCEDURE
Intervention: Portal vein embolization
Description: Portal vein emboliazation with either NBCA or micro particles.
Study: NCT06397326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return to work coordinator + PRATICAdr 2.0
Description: The Return to work coordinator (RTW-C) uses PRATICAdr. 2.0 (web application).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Return to work coordinator only
Description: The Return to work coordinator (RTW-C) intervenes on employees on sick leave as usual
Study: NCT04887064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered as an oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered as an oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered as an oral tablet.
Study: NCT04732598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + bevacizumab therapy
Description: The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV
Study: NCT04996030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-2101
Description: SY-2101 will be administered per dose and schedule specified in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-2101
Description: SY-2101 will be administered per dose and schedule specified in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-2101
Description: SY-2101 will be administered per dose and schedule specified in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-2101
Description: SY-2101 will be administered per dose and schedule specified in arm description.
Study: NCT04732598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + bevacizumab + atezolizumab
Description: The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Atezolizumab\] 840 mg/body, day 1,15, IV \[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV
Study: NCT04996030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: IV ATO will be administered per dose and schedule specified in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: IV ATO will be administered per dose and schedule specified in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: IV ATO will be administered per dose and schedule specified in arm description.
Study: NCT05672563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline infusion sonography for evaluation of cesarean scar
Description: The intervention included the usage of balloon-less GIS catheter with a soft tapered tip inserted into the endocervical canal, with no use of a tenaculum or a cervical dilatator. Normal saline is slowly introduced into the uterine cavity via the catheter until achieving satisfactory distension and visualization of the uterine cavity using trans-vaginal ultra-sonographic imaging.
Study: NCT05076227

Intervention type: DRUG
Intervention: IM injection of vaccination (mRNA vaccination)
Description: mRNA vaccination

Intervention type: DRUG
Intervention: IM injection of vaccination (mRNA vaccination)
Description: mRNA vaccination
Study: NCT05362500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycolic Acid 70%
Description: Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
Study: NCT05470192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong exercise training
Description: Before and after the qigong exercises, 10-minute exercises will be done to stretch the large muscle groups for warm-up-cooling purposes.~The entire Baduanjin exercise consists of 8 postures:~preparation position~1. Raising arms with palms up,~2. Shooting arrows left and right like an archer in a semi-crouching position~3. Keeping one arm up~4. Looking back with trunk rotations in a semi-crouching position~5. Nodding the head and lowering the body to relieve stress,~6. Fisting and staring~7. Touching feet with hands touching back and legs~8. Raising and lowering heels
Study: NCT05076227

Intervention type: DRUG
Intervention: IM injection of vaccination (mRNA vaccination)
Description: mRNA vaccination

Intervention type: DRUG
Intervention: IM injection of vaccination (vector based vaccination)
Description: vector based vaccination

Intervention type: DRUG
Intervention: IM injection of vaccination (vector based vaccination)
Description: vector based vaccination
Study: NCT06430905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-502 and HB-501 alternating 2-vector therapy Dose Level 1
Description: Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-502 and HB-501 alternating 2-vector therapy Dose Level 2
Description: Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administration of placebo to 5 participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administration of placebo to 5 participants.
Study: NCT06505109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESST
Description: Subjects randomized to the RESST intervention will receive on top of standard rehabilitation a behavioural group intervention focussing on improving sleep and stress. This intervention will consist of 5 till 6 meetings of 90 till 120 minutes in the local rehabilitation centre during a time period of 3 till 4 months.
Study: NCT05326815

Intervention type: DIAGNOSTIC_TEST
Intervention: N-Telopeptide, Bone Marker
Description: This is a prospective specimen collection cohort study to evaluate the correlation between serum and urine values of the bone marker of interest (N-Telopeptide), and their association with baseline DEXA scan measures and fracture risk within 6 months.~Study samples will be obtained longitudinally. One collection of both serum and urine collection will be obtained. The urine will be collected as second void of day and at the same time the blood collection is drawn.
Study: NCT04631900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Christianity approach as framework for spiritual intervention
Description: Intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group. Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose.
Study: NCT05390021

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent
Description: The research study procedures include a screening for eligibility and a single study visit. PET/MRI in one study visit of approximately four hours.
Study: NCT05635305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoliflodacin Patheon
Description: Zoliflodacin Patheon formulation to be compared with Zoliflodacin Dr Reddy's formulation during BE study (cohort 1).~Itraconazole will be administered with Zoliflodacin Patheon formulation during DDI study (cohort 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoliflodacin Patheon
Description: Zoliflodacin Patheon formulation to be compared with Zoliflodacin Dr Reddy's formulation during BE study (cohort 1).~Itraconazole will be administered with Zoliflodacin Patheon formulation during DDI study (cohort 2)
Study: NCT06390878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodiversity
Description: In rewilding kindergartens, the yards are modified with biological elements, i.e., vegetation and plantation will be added to the yards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playground equipment
Description: Playground equipment that increase the physical activity of children will be added to the kindergarten yards.
Study: NCT04582799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECCO2R
Description: Extracorporeal CO2 Removal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: Non-invasive ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV
Description: Non-invasive ventilation
Study: NCT06059638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated
Description: Antihypertensive therapy utilizing atrioventricular interval modulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
Description: AVIM therapy is deactivated
Study: NCT05526521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Injection solution Subcutaneous
Study: NCT05287711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: In Session 1, the therapist provides personalized feedback on a range of assessment variables, including alcohol consumption levels, negative consequences from alcohol use, and family risk of alcoholism. Sessions 2-4 are follow-through sessions in which the therapist attempts to help the Veteran participant establish or reaffirm a commitment to an action plan for addressing alcohol concerns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Education Control
Description: Will consist of 4 weekly individual sessions, approximately 60 minutes each. AE therapists will explain that their job is to provide the Veteran participants with information and education about the effects of alcohol, and that it is up to the Veteran participant to use this information as he sees fit. In each session, the Veteran participant will watch an educational videotape in a comfortable consulting room and will be given an opportunity to discuss the videotape with the project therapist for approximately 10 minutes. Written educational materials will supplement the information provided in the videos, and the therapist will ask several structured questions to determine whether the Veteran participant understood the material presented in the video.
Study: NCT04745351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as Intravenous (IV) infusion once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RDV Placebo
Description: Administered as IV saline once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT06062056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR alert
Description: An EHR alert will be fired if a behavioral health patient is missing a COVID-19 or influenza vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: In response to the alert and using support tools in the EHR, the behavioral health clinician will integrate motivational interviewing into the counseling session to discuss vaccine hesitancy (if it is deemed appropriate based on patient needs and clinical judgment).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warm hand off to nurse
Description: For patients interested in vaccination following motivational interviewing, the behavioral health clinician will do a warm hand off to a nurse for vaccination
Study: NCT05287711

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Supportive telephone monitoring sessions that ensure equal spacing between assessments across conditions and equal number of therapist contacts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength at Home
Description: IPV intervention which consists of 12 weekly, 2-hour cognitive-behavioral sessions offered in a closed group format and co-led by doctoral level male and female therapists. Strength at Home is based on a social information processing model of trauma and IPV and provides material covering psychoeducation regarding trauma and IPV, conflict and anger management skills, assertiveness training, and skills in stress management and communication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength at Home
Description: IPV intervention which consists of 12 weekly, 2-hour cognitive-behavioral sessions offered in a closed group format and co-led by doctoral level male and female therapists. Strength at Home is based on a social information processing model of trauma and IPV and provides material covering psychoeducation regarding trauma and IPV, conflict and anger management skills, assertiveness training, and skills in stress management and communication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Strength at Home
Description: IPV intervention which consists of 12 weekly, 2-hour cognitive-behavioral sessions offered in a closed group format and co-led by doctoral level male and female therapists. Strength at Home is based on a social information processing model of trauma and IPV and provides material covering psychoeducation regarding trauma and IPV, conflict and anger management skills, assertiveness training, and skills in stress management and communication.
Study: NCT05090644

Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS
Study: NCT06610968

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (Cholecalciferol )
Description: 5000 IU Vitamin D (as cholecalciferol) capsules (Vitamin D3 125 mcg \[5,000 IU\], Pure Encapsulation, LLC) daily
Study: NCT06610968

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: One placebo capsule (Zeebo Imagine, Zeebo) daily.
Study: NCT06610175

Intervention type: DEVICE
Intervention: Quantitative MRI and anatomical MRI
Description: The total scanning time will be approximately 40 minutes. Additionally, 10 healthy participants and 10 patients with symptomatic CDDD will undergo a second MRI with additional sequences for assessment of reproducibility on another day/time. Also: included participants will undergo neurologic examination and fill out questionnaires for NDI, VAS-arm, VAS-neck, WA-SI, EQ-5D-5L, CSI, mJOA and Nurick.
Study: NCT05669157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiography request by nurse
Description: Intervention group with radiography requested by the IRN instead of the physician. The radiography will be interpreted by the physician afterwards, according to current practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiography request by physician
Description: The physician prescribed the X-ray, the X-ray technician carries out the imagery and the physician interprets it afterwards
Study: NCT06609629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective lung recruitment
Description: A bronchial blocker with a lumen is inserted in one inferior pulmonary lobe using a fibroscope. The baloon of the blocker is expended to isolate the lobe. A second ventilator is used to apply a pressure of 45cmH2o through the lumen of the blocker. The recruiting pressure is maintained 30 to 60 second. After the procedure, the blocker is removed and the procedure is repeated in the controlateral inferior lobe.
Study: NCT06610331

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: FREE GİNGİVAL GRAFT
Description: Free Gingival Graft removal from the palate donor area for the treatment of gingival recession

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FREE GİNGİVAL GRAFT
Description: Free Gingival Graft removal from the palate donor area for the treatment of gingival recession

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyvinylpyrrolidone sodium hyaluronate gel
Description: Patients are told to gargle with a mouthwash containing polyvinyl pyrrolidone sodium hyaluronate twice a day for 2 weeks. 15 ml (1 tablespoon) of mouthwash containing polyvinyl pyrrolidone sodium hyaluronate is poured into a glass and approximately 40 ml (3 tablespoons) of water is added and mixed well, then it is shaken for at least 1 minute, making contact with the entire mouth.
Study: NCT06610656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacifier and White Noise Therapy
Description: Infants will receive both pacifier and white noise therapy to enhance sleep quality and reduce restlessness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pacifier therapy
Description: Infants will receive pacifier therapy to enhance sleep quality and reduce restlessness
Study: NCT06610214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPACT-care intervention
Description: 1, Training of Healthcare Staff; 2, Development of Medication Summary; 3, Information Package for Patient and/or Caregiver; 4, Discharge Coaching; 5, Post-Discharge follow-Up call
Study: NCT06609746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thyme extract
Description: Three Gastrolit capsules daily with a low FODMAP diet for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules daily with a low FODMAP diet for 8 weeks
Study: NCT04647435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APSCTC
Description: APSCTC + Toragesic® placebo + Tramal® placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toragesic®
Description: APSCTC placebo + Toragesic® + Tramal® placebo
Study: NCT06470581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin type A 75 IU mixed with 3 ml of non-preserved saline solution are injected in the patients in the control and botulinum toxin groups, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin type A 75 IU mixed with 3 ml of non-preserved saline solution are injected in the patients in the control and botulinum toxin groups, respectively.
Study: NCT06069362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual physiotherapy and neurodynamic exercises
Description: * Cervical passive mobilisation techniques and techniques of the anatomical structures surrounding the nerve. These techniques aim to open the nerve root foramen. They are gentle traction techniques and contralateral lateral glide mobilisation techniques. Interface techniques for scalenes will also be included.~* Home exercises for cervical mobility and neurodynamic sliders of the upper extremity: Patients will be taught progressive upper extremity neurodynamic sliders, starting with gentle movement and progressing to exercises involving more movement based on the patient's irritability.